(ANSA) - ROME, APRIL 06 - Oral semaglutide, a drug useful for the treatment against type 2 diabetes, has also arrived in Italy, reimbursed by the National Health Service (NHS). 1 by oral administration, to be taken once daily.
"Despite the availability of a wide spectrum of therapeutic options and the demonstration of the importance of adequate metabolic control to prevent or delay the onset of complications of type 2 diabetes, a percentage of patients do not reach the desired therapeutic targets", says Graziano Di Cianni, director of the '' Complex operating unit for diabetes and metabolic diseases of the North-West Tuscany Local Health Authority.
For Agostino Consoli, full professor of Endocrinology at the University of Chieti and director of the Local Unit of Endocrinology and Metabolism of the Asl diPescara, "hyperglycemia, together with excess weight, arterial hypertension, alterations in lipid metabolism, smoking represents a risk factor for cardiovascular disease that is modifiable ".
"The simultaneous treatment of multiple risk factors certainly contributes to slowing down or preventing cardiovascular diseases on an atherosclerotic basis, such as heart attacks and strokes, which are among the main causes of disability and mortality in Italy - adds Consoli - At the moment, however, as many as 80 per cent of people with type 2 diabetes does not reach target levels of glycated hemoglobin, blood pressure and low density lipoproteins ".
(HANDLE).